Clinicopathological features and prognosis of breast cancer with low HER2 status evaluated by fluorescence <em>in situ</em> hybridization

Sato,Ayana; Maeda,Yuka; Matsumoto,Akiko; Ikeda,Tatsuhiko; Jinno,Hiromitsu

doi:10.3892/ol.2024.14838

Clinicopathological features and prognosis of breast cancer with low HER2 status evaluated by fluorescence in situ hybridization

Authors:
- Ayana Sato
- Yuka Maeda
- Akiko Matsumoto
- Tatsuhiko Ikeda
- Hiromitsu Jinno
View Affiliations

Affiliations: Department of Surgery, Teikyo University School of Medicine, Tokyo 173‑8606, Japan
Published online on: December 6, 2024 https://doi.org/10.3892/ol.2024.14838
Article Number: 92
Copyright: © Sato et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although trastuzumab deruxtecan improves the prognosis of patients with HER2‑low breast cancer, the characteristics and prognostic value of low HER2 status remains to be elucidated. A prospective database of patients with clinical stage I to III breast cancer who underwent surgery between September 2012 and October 2022 at Teikyo University Hospital (Tokyo, Japan) were analyzed. HER2 was evaluated using fluorescence in situ hybridization assay, and HER2‑low and HER2‑negative was defined as HER2/CEP17 ratio ≥1.0, and <1.0, respectively. The median age and Ki67 score of the 1,024 patients were 56.0 years (range, 23.0‑93.0 years) and 15.0% (range, 0.5‑99.0%), respectively. Overall, 908 (88.7%) patients were hormone receptor positive. Among all patients, 902 (88.1%) had HER2‑low tumors and 122 (11.9%) had HER2‑negative tumors. Positive rates for estrogen receptor (ER) and progesterone receptor (PgR) were significantly higher in HER2‑low compared with HER2‑negative patients [ER: 804 (89.1%) patients vs. 99 (81.1%) patients, P=0.021; PgR: 723 (80.1%) patients vs. 86 (70.5%) patients, P=0.023]. The median Ki67 score was significantly lower in HER2‑low compared with HER2‑negative patients (14.5 vs. 18.5%; P=0.013). With a median follow‑up time of 46.2 months, the overall survival (OS) was significantly improved in HER2‑low compared with HER2‑negative patients (97.4 vs. 96.7%; P=0.029). Multivariate logistic regression analyses revealed that HER2‑low status was not an independent factor for OS. The findings of the present study suggest that HER2‑low status may not have a significant association with prognosis, despite a significant association between Ki67 and hormone receptor expression.

View Figures

View References

1	Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L and Bloom KJ: The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist. 8:307–325. 2003. View Article : Google Scholar : PubMed/NCBI
2	Grant S, Qiao L and Dant P: Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci. 7:d376–d389. 2002. View Article : Google Scholar : PubMed/NCBI
3	Zhang H, Katerji H, Turner BM and Hicks DG: HER2-low breast cancers: New opportunities and challenges. Am J Clin Pathol. 157:328–336. 2022. View Article : Google Scholar : PubMed/NCBI
4	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
5	Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
6	Paik S, Kim C and Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 358:1409–1411. 2008. View Article : Google Scholar : PubMed/NCBI
7	Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, et al: NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol. 38:444–453. 2020. View Article : Google Scholar : PubMed/NCBI
8	Ergun Y, Ucar G and Akagunduz B: Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 115:1025382023. View Article : Google Scholar : PubMed/NCBI
9	Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, et al: HER2-low breast cancer: Pathological and clinical landscape. J Clin Oncol. 38:1951–1962. 2020. View Article : Google Scholar : PubMed/NCBI
10	Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, et al: Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 8:1177–1183. 2022.PubMed/NCBI
11	Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, Zabernigg AF, Egle D, Sandholzer M, et al: Landscape of HER2-low metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-registry. Breast Cancer Res. 23:1122021. View Article : Google Scholar : PubMed/NCBI
12	Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, et al: HER2-low-positive breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer. 8:662022. View Article : Google Scholar : PubMed/NCBI
13	Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, et al: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 7:12021. View Article : Google Scholar : PubMed/NCBI
14	Tarantino P, Niman S, Erick T, Priedigkeit N, Harrison BT, Giordano A, Nakhlis F, Bellon JR, Parker T, Strauss S, et al: HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. Eur J Cancer. 174:277–286. 2022. View Article : Google Scholar : PubMed/NCBI
15	Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, Sugino K, Kataoka A, Kotani H, Yoshimura A, et al: The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer. 29:234–241. 2022. View Article : Google Scholar : PubMed/NCBI
16	Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, Sotiriou C and de Azambuja E: HER2-low breast cancer: Molecular characteristics and prognosis. Cancers (Basel). 13:28242021. View Article : Google Scholar : PubMed/NCBI
17	Mouabbi J, Singareeka Raghavendra A, Bassett R Jr, Hassan A, Tripathy D and Layman RM: Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy. JAMA Netw Open. 6:e23130172023. View Article : Google Scholar : PubMed/NCBI
18	Park WK, Nam SJ, Kim SW, Lee JE, Yu J, Lee SK, Ryu JM and Chae BJ: The prognostic impact of HER2-low and menopausal status in triple-negative breast cancer. Cancers (Basel). 16:25662024. View Article : Google Scholar : PubMed/NCBI
19	Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, et al: Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 22:1151–1161. 2021. View Article : Google Scholar : PubMed/NCBI